NCT05217407 Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
| NCT ID | NCT05217407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Center, Japan |
| Condition | Rare Malignant Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-11-30 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-11-30 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.
Eligibility Criteria
Inclusion Criteria: 1. Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.) 2. Patients with Advanced stage cancer. Exclusion Criteria: 1\. Patients with complications of cognitive impairment.
Contact & Investigator
Noboru Yamamoro, MD, PhD
PRINCIPAL INVESTIGATOR
National Cancer Center Hospital, Japan
Frequently Asked Questions
Who can join the NCT05217407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rare Malignant Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05217407 currently recruiting?
Yes, NCT05217407 is actively recruiting participants. Contact the research team at ncch2007_office@ml.res.ncc.go.jp for enrollment information.
Where is the NCT05217407 trial being conducted?
This trial is being conducted at Chuo-ku, Japan, Johor Bahru, Malaysia, Pulau Pinang, Malaysia, Kuching, Malaysia and 11 additional locations.
Who is sponsoring the NCT05217407 clinical trial?
NCT05217407 is sponsored by National Cancer Center, Japan. The principal investigator is Noboru Yamamoro, MD, PhD at National Cancer Center Hospital, Japan. The trial plans to enroll 1,000 participants.